NFE2L2 and diabetes mellitus: Considering how the Nrf2/HO-1 pathway is disrupted in the setting of diabetes, we conducted subsequent experiments to determine whether pretreatment with the Nrf2 agonist TBHQ [49] could attenuate RI/RI in diabetic rats.